patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_296777 | REC_0004701 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15 | 86 | female | 2 | 20 | 5.3 | 1 | alectinib 600 mg BID | 12 | false | MSI-H | 2026-03-15T05:35:58.008842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520928 | REC_0004702 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 12.7 | 82 | male | 1 | 14 | 6.4 | 0 | osimertinib 80 mg daily | 17 | true | MSS | 2026-03-15T05:35:58.009075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135910 | REC_0004703 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.8 | 83 | female | 2 | 44 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.009308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372106 | REC_0004704 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.5 | 71 | female | 2 | 13 | 4 | 7 | entrectinib 600 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:58.009542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407200 | REC_0004705 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.2 | 64 | female | 1 | 19 | 3.8 | 6 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.009777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622195 | REC_0004706 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 11.3 | 70 | female | 1 | 18 | 6.4 | 6 | pembrolizumab 200 mg q3w | 12.7 | true | MSS | 2026-03-15T05:35:58.010008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174107 | REC_0004707 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 5 | 66 | female | 1 | 6 | 4.6 | 7 | pembrolizumab 200 mg q3w | 12.9 | false | MSS | 2026-03-15T05:35:58.010348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141624 | REC_0004708 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 7 | 73 | male | 2 | 15 | 6.2 | 4 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:35:58.010585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164932 | REC_0004709 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 12.5 | 66 | female | 1 | 18 | 5.6 | 6 | entrectinib 600 mg daily | 4.9 | false | MSI-H | 2026-03-15T05:35:58.010819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542061 | REC_0004710 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 19.6 | 74 | female | 3 | 18 | 6.9 | 2 | sotorasib 960 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:35:58.011053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_882467 | REC_0004711 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 4 | 64 | male | 1 | 42 | 8 | 0 | pembrolizumab 200 mg q3w | 21.2 | false | MSS | 2026-03-15T05:35:58.011288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871952 | REC_0004712 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 3.1 | 67 | male | 1 | 28 | 5.4 | 1 | pembrolizumab 200 mg q3w | 23.1 | false | MSS | 2026-03-15T05:35:58.011522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844706 | REC_0004713 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 9.4 | 61 | female | 1 | 25 | 5.7 | 4 | alectinib 600 mg BID | 7.3 | false | MSS | 2026-03-15T05:35:58.011753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787657 | REC_0004714 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.7 | 52 | male | 0 | 25 | 8.1 | 6 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:58.011987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569496 | REC_0004715 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.8 | 62 | female | 0 | 8 | 4.6 | 6 | pembrolizumab 200 mg q3w | 9.6 | true | MSS | 2026-03-15T05:35:58.012280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774842 | REC_0004716 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 15.5 | 78 | female | 2 | 10 | 3 | 3 | entrectinib 600 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:58.012537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834881 | REC_0004717 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.7 | 57 | female | 1 | 28 | 4.3 | 2 | pembrolizumab 200 mg q3w | 20 | true | MSS | 2026-03-15T05:35:58.012792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717228 | REC_0004718 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 10.9 | 73 | female | 2 | 17 | 7.2 | 2 | alectinib 600 mg BID | 20.1 | false | MSI-H | 2026-03-15T05:35:58.013033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183931 | REC_0004719 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 7.1 | 74 | female | 2 | 27 | 5.5 | 6 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:58.013270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633370 | REC_0004720 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 9.7 | 73 | female | 2 | 70 | 4.2 | 2 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:58.013615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138020 | REC_0004721 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.1 | 67 | female | 0 | 18 | 6.2 | 7 | sotorasib 960 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:58.013878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989090 | REC_0004722 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.6 | 54 | male | 0 | 15 | 5.6 | 3 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:58.014128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785699 | REC_0004723 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 12.8 | 76 | female | 2 | 10 | 5.7 | 3 | entrectinib 600 mg daily | 7.2 | true | MSS | 2026-03-15T05:35:58.014366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683248 | REC_0004724 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 8.4 | 70 | male | 1 | 9 | 7 | 2 | sotorasib 960 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:58.014603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373331 | REC_0004725 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.7 | 78 | female | 1 | 14 | 6.2 | 8 | osimertinib 80 mg daily | 8.1 | false | MSS | 2026-03-15T05:35:58.014836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725527 | REC_0004726 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 18.9 | 67 | female | 0 | 8 | 5.4 | 8 | entrectinib 600 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:35:58.015075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440492 | REC_0004727 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.7 | 70 | female | 1 | 35 | 5.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 17.6 | true | MSS | 2026-03-15T05:35:58.015308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597219 | REC_0004728 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.5 | 64 | female | 0 | 4 | 6.1 | 2 | sotorasib 960 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:58.015544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546481 | REC_0004729 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 11.7 | 53 | female | 0 | 10 | 6.7 | 6 | osimertinib 80 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:58.015785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412230 | REC_0004730 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.6 | 76 | female | 2 | 17 | 3.8 | 7 | entrectinib 600 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:58.016028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127984 | REC_0004731 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.4 | 65 | male | 0 | 53 | 5.2 | 1 | pembrolizumab 200 mg q3w | 26.5 | false | MSS | 2026-03-15T05:35:58.016383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849560 | REC_0004732 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.7 | 84 | female | 2 | 62 | 4 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.8 | true | MSS | 2026-03-15T05:35:58.016655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229559 | REC_0004733 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 3.9 | 76 | male | 1 | 30 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:58.017089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896673 | REC_0004734 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.5 | 56 | male | 0 | 19 | 5.2 | 1 | osimertinib 80 mg daily | 26.6 | false | MSS | 2026-03-15T05:35:58.017430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550940 | REC_0004735 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.7 | 57 | female | 0 | 6 | 2.6 | 3 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:58.017690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403111 | REC_0004736 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 7.7 | 67 | female | 1 | 5 | 6.4 | 6 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:35:58.017934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172252 | REC_0004737 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.3 | 58 | male | 0 | 23 | 7.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:35:58.018182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185406 | REC_0004738 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.1 | 69 | male | 0 | 25 | 3 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:35:58.018435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356483 | REC_0004739 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.6 | 83 | female | 2 | 10 | 7 | 5 | entrectinib 600 mg daily | 18.4 | false | MSS | 2026-03-15T05:35:58.018683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607904 | REC_0004740 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 12.2 | 54 | male | 0 | 6 | 5.1 | 3 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:58.018928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462439 | REC_0004741 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 39 | 10.8 | 88 | female | 1 | 12 | 7.6 | 4 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:35:58.019174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270106 | REC_0004742 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.5 | 66 | female | 1 | 8 | 6 | 4 | sotorasib 960 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:35:58.019418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945154 | REC_0004743 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.2 | 67 | male | 0 | 27 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.5 | false | MSS | 2026-03-15T05:35:58.019666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383888 | REC_0004744 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 12.1 | 63 | male | 0 | 9 | 4.3 | 5 | alectinib 600 mg BID | 6 | true | MSI-H | 2026-03-15T05:35:58.019924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954141 | REC_0004745 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.2 | 57 | male | 1 | 49 | 4.8 | 8 | pembrolizumab 200 mg q3w | 8.7 | true | MSS | 2026-03-15T05:35:58.020215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923948 | REC_0004746 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 13.8 | 63 | male | 0 | 13 | 6.8 | 2 | osimertinib 80 mg daily | 33.4 | false | MSI-H | 2026-03-15T05:35:58.020612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204456 | REC_0004747 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 9.4 | 71 | male | 3 | 0 | 6.6 | 2 | pembrolizumab 200 mg q3w | 23.1 | true | MSS | 2026-03-15T05:35:58.020867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907543 | REC_0004748 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.8 | 67 | female | 0 | 29 | 5.9 | 6 | entrectinib 600 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.021107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975795 | REC_0004749 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.2 | 58 | male | 1 | 4 | 6 | 7 | sotorasib 960 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:58.021346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472481 | REC_0004750 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 7.4 | 65 | female | 0 | 5 | 6.4 | 7 | pembrolizumab 200 mg q3w | 8.2 | false | MSS | 2026-03-15T05:35:58.021581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529416 | REC_0004751 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 16 | 77 | female | 2 | 23 | 7.8 | 1 | alectinib 600 mg BID | 18.6 | false | MSI-H | 2026-03-15T05:35:58.021812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560450 | REC_0004752 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.5 | 51 | female | 0 | 20 | 3.4 | 7 | sotorasib 960 mg daily | 14.2 | true | MSI-H | 2026-03-15T05:35:58.022046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892322 | REC_0004753 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 20 | 7.1 | 77 | female | 2 | 40 | 3.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 38.2 | false | MSS | 2026-03-15T05:35:58.022278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734275 | REC_0004754 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 15.3 | 73 | female | 2 | 16 | 5.2 | 0 | sotorasib 960 mg daily | 42.8 | true | MSI-H | 2026-03-15T05:35:58.022515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729388 | REC_0004755 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.9 | 82 | female | 2 | 42 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:35:58.022744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855177 | REC_0004756 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.7 | 59 | male | 0 | 0 | 5.2 | 2 | alectinib 600 mg BID | 20.7 | false | MSI-H | 2026-03-15T05:35:58.022980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332238 | REC_0004757 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.9 | 69 | female | 1 | 73 | 4.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.7 | true | MSS | 2026-03-15T05:35:58.023208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247280 | REC_0004758 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 20.3 | 76 | female | 1 | 13 | 7 | 2 | pembrolizumab 200 mg q3w | 14.6 | true | MSS | 2026-03-15T05:35:58.023439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618470 | REC_0004759 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.2 | 75 | female | 0 | 58 | 6.8 | 8 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:35:58.023721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711747 | REC_0004760 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.9 | 73 | male | 1 | 16 | 3.5 | 4 | osimertinib 80 mg daily | 9 | true | MSI-H | 2026-03-15T05:35:58.023960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438597 | REC_0004761 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 15.9 | 68 | female | 0 | 15 | 3 | 2 | alectinib 600 mg BID | 28.6 | false | MSS | 2026-03-15T05:35:58.024252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518263 | REC_0004762 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 11.7 | 65 | male | 0 | 20 | 4.1 | 2 | entrectinib 600 mg daily | 30.8 | false | MSI-H | 2026-03-15T05:35:58.024511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698667 | REC_0004763 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.7 | 57 | female | 0 | 26 | 4.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:58.024750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475816 | REC_0004764 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.1 | 65 | male | 0 | 17 | 5.8 | 6 | alectinib 600 mg BID | 11.8 | true | MSS | 2026-03-15T05:35:58.024986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170101 | REC_0004765 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.1 | 60 | male | 0 | 27 | 5.1 | 4 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:35:58.025217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895953 | REC_0004766 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 15.2 | 77 | female | 2 | 23 | 6.4 | 2 | sotorasib 960 mg daily | 15.8 | false | MSI-H | 2026-03-15T05:35:58.025451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316721 | REC_0004767 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.6 | 84 | female | 1 | 18 | 4.9 | 6 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:58.025693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308238 | REC_0004768 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 19 | 17 | 61 | female | 1 | 13 | 4.6 | 0 | sotorasib 960 mg daily | 60.6 | true | MSI-H | 2026-03-15T05:35:58.025930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552863 | REC_0004769 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 15.1 | 64 | male | 0 | 18 | 5.7 | 1 | alectinib 600 mg BID | 24.4 | true | MSI-H | 2026-03-15T05:35:58.026167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169004 | REC_0004770 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 9.2 | 71 | female | 2 | 17 | 6.8 | 7 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:58.026399+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483296 | REC_0004771 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 13.3 | 55 | male | 0 | 23 | 6.5 | 2 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:58.026635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561986 | REC_0004772 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.8 | 61 | female | 0 | 32 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.7 | true | MSS | 2026-03-15T05:35:58.026932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603275 | REC_0004773 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.2 | 67 | male | 0 | 23 | 6 | 7 | sotorasib 960 mg daily | 8.4 | false | MSS | 2026-03-15T05:35:58.027180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679898 | REC_0004774 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.1 | 83 | male | 2 | 25 | 7.3 | 5 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:58.027419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805247 | REC_0004775 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 14.8 | 79 | female | 2 | 12 | 6.1 | 5 | entrectinib 600 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:58.027655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491621 | REC_0004776 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.5 | 68 | female | 0 | 0 | 4.6 | 1 | osimertinib 80 mg daily | 5.2 | true | MSS | 2026-03-15T05:35:58.027887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326955 | REC_0004777 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.2 | 70 | female | 2 | 9 | 4.9 | 7 | sotorasib 960 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:58.028176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471376 | REC_0004778 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 4.4 | 66 | female | 1 | 59 | 6 | 6 | pembrolizumab 200 mg q3w | 11.2 | true | MSS | 2026-03-15T05:35:58.028415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842555 | REC_0004779 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.6 | 70 | female | 0 | 15 | 6.1 | 4 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.028654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510577 | REC_0004780 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 15.3 | 79 | male | 0 | 18 | 6.3 | 3 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:58.028902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135168 | REC_0004781 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.6 | 62 | female | 1 | 10 | 5.5 | 5 | pembrolizumab 200 mg q3w | 6.5 | false | MSS | 2026-03-15T05:35:58.029139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105354 | REC_0004782 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.3 | 79 | male | 2 | 49 | 4.9 | 6 | pembrolizumab 200 mg q3w | 6.6 | false | MSS | 2026-03-15T05:35:58.029373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336928 | REC_0004783 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 10.9 | 49 | male | 0 | 14 | 6.6 | 5 | pembrolizumab 200 mg q3w | 14.7 | true | MSI-H | 2026-03-15T05:35:58.029612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228645 | REC_0004784 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 17.8 | 74 | female | 1 | 12 | 6 | 2 | pembrolizumab 200 mg q3w | 19 | true | MSI-H | 2026-03-15T05:35:58.029847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144608 | REC_0004785 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 17.7 | 76 | female | 1 | 19 | 5 | 5 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:58.030170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689784 | REC_0004786 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.2 | 70 | female | 0 | 17 | 4.2 | 1 | sotorasib 960 mg daily | 21 | false | MSS | 2026-03-15T05:35:58.030412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465628 | REC_0004787 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 3 | 67 | female | 0 | 23 | 5.1 | 1 | pembrolizumab 200 mg q3w | 24.5 | true | MSS | 2026-03-15T05:35:58.030648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343988 | REC_0004788 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 11.7 | 66 | male | 0 | 18 | 5.1 | 2 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.030890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806908 | REC_0004789 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 5.6 | 73 | female | 1 | 1 | 3.6 | 2 | sotorasib 960 mg daily | 25.7 | false | MSS | 2026-03-15T05:35:58.031125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794109 | REC_0004790 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.8 | 59 | male | 1 | 16 | 7.6 | 5 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:58.031360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169572 | REC_0004791 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.8 | 58 | male | 1 | 18 | 4.8 | 4 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:58.031596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187934 | REC_0004792 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 12.4 | 75 | female | 2 | 7 | 3 | 0 | sotorasib 960 mg daily | 54.4 | false | MSI-H | 2026-03-15T05:35:58.031830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724407 | REC_0004793 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.2 | 70 | female | 2 | 52 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:35:58.032064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188962 | REC_0004794 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 10.3 | 67 | male | 1 | 23 | 5 | 2 | osimertinib 80 mg daily | 22.8 | false | MSI-H | 2026-03-15T05:35:58.032342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520382 | REC_0004795 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 5.1 | 70 | male | 1 | 19 | 4.9 | 8 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:35:58.032575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720692 | REC_0004796 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.5 | 65 | female | 0 | 17 | 5.1 | 4 | entrectinib 600 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:58.032810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323222 | REC_0004797 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.8 | 73 | female | 1 | 12 | 3.9 | 8 | pembrolizumab 200 mg q3w | 14.2 | false | MSS | 2026-03-15T05:35:58.033041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277028 | REC_0004798 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 14.8 | 71 | female | 1 | 14 | 3.3 | 9 | alectinib 600 mg BID | 12 | true | MSS | 2026-03-15T05:35:58.033335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435373 | REC_0004799 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.4 | 59 | female | 0 | 18 | 6.9 | 6 | pembrolizumab 200 mg q3w | 8.9 | false | MSS | 2026-03-15T05:35:58.033570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750846 | REC_0004800 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 17.5 | 51 | male | 0 | 21 | 5.5 | 4 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:58.033808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.